Table 1.
Medication | Number of subjects exposed | Total patient-years of exposure |
---|---|---|
Adalimumab | 469 | 495.3 |
Certolizumab pegol | 9 | 2.0 |
Etanercept | 324 | 194.6 |
Golimumab | 6 | 1.5 |
Infliximab | 527 | 840.6 |
All TNFi | 1033 | 1564.3 |
aBecause many subjects were exposed to more than one TNFi, the total number of subjects does not equal the sum of the subjects for the individual medications